Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
Kura Oncology and Kyowa Kirin announced the publication of updated results from the KOMET-007 Phase 1a/b trial in the journal Blood. The data showed an 87% objective response rate and 70% composite complete remission rate in venetoclax-naïve patients with relapsed/refractory NPM1-mutated AML treated with ziftomenib plus venetoclax and azacitidine.
Key figures
- Drug Name
- ziftomenib
- Phase Of Trial
- Phase 1a/b
- Patient count
- 64
- Crc venetoclax naive
- 70%
- Orr venetoclax naive
- 87%
- Crc venetoclax experienced
- 24%
- Orr venetoclax experienced
- 48%
- Differentiation syndrome rate
- 3%
- Mrd negativity venetoclax naive
- 75%
- Median os venetoclax experienced
- 7.4 months
- Median crc duration venetoclax naive
- 9.2 months
- Mrd negativity venetoclax experienced
- 50%
- Median crc duration venetoclax experienced
- 8.6 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.